SCHEMBL6002937

SCHEMBL6002937

[CH](c1ccccc1)C1CCNCC1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC18A3 Q16572 1/20 0.48
SIGMAR1 Q99720 1/20 0.48
HRH1 P35367 3/20 0.44
GBA1 P04062 1/20 0.44
KDM1A O60341 4/20 0.43
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
CYP2D6 P10635 1/20 0.41
SCN1A P35498 1/20 0.41
KMT2A Q03164 1/20 0.41
SCN2A Q99250 1/20 0.41
SCN3A Q9NY46 1/20 0.41
OPRM1 P35372 1/20 0.39
HTR2C P28335 2/20 0.38
MAOB P27338 3/20 0.38
MAOA P21397 1/20 0.38
HPGDS O60760 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8074183 0.88 SLC18A3 (0.41) SLC18A3SIGMAR1HRH1GBA1KDM1A
SCHEMBL674275 0.84 MAOB (0.46) KDM1ALMNACYP2D6MAOB
SCHEMBL316481 0.79 POLB (0.45) MAOB
SCHEMBL1119433 0.79 ALDH1A1 (0.42) LMNACYP2D6MAOB
SCHEMBL6002534 0.79 HTR3A (0.44) SIGMAR1CYP2D6HTR2C
SCHEMBL7249057 0.79 SLC6A2 (0.39) LMNA
SCHEMBL8481040 0.79 AKT1 (0.39) MEN1KMT2AMAOA
SCHEMBL20015683 0.79 KDM1A (0.51) SLC18A3SIGMAR1KDM1ALMNAMAOB
SCHEMBL818902 0.79 KDM1A (0.51) SLC18A3SIGMAR1KDM1ALMNAMAOB
SCHEMBL27140897 0.79 KDM1A (0.51) SLC18A3SIGMAR1KDM1ALMNAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3989997-A1 COMPOUNDS AND METHODS FOR TREATING CANCER, VIRAL INFECTIONS, AND ALLERGIC CONDITIONS Washington University (US) 2022-05-04 EP disclosed
WO-2020264187-A1 COMPOUNDS AND METHODS FOR TREATING CANCER, VIRAL INFECTIONS, AND ALLERGIC CONDITIONS JANETKA JAMES (US) 2020-12-30 WO disclosed
EP-2694707-A1 MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME Cornell University (US) 2014-02-12 EP disclosed
WO-2013058824-A1 MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME CORNELL UNIVERSITY (US) 2013-04-25 WO disclosed
CN-100497345-C 2, 3-dihydro-6-nitroimidazolo [2,1-b] oxazole compounds for the treatment of tuberculosis OTSUKA PHARMA CO LTD (JP) 2009-06-10 CN disclosed
CN-1878777-A 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis OTSUKA PHARMA CO LTD (JP) 2006-12-13 CN disclosed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 WO disclosed
EP-1091945-A1 CYCLIC CARBAMATES AND ISOXAZOLIDINES AS IIB/IIIA ANTAGONISTS Du Pont Pharmaceuticals Company (US) 2001-04-18 EP disclosed
WO-2000000481-A1 CYCLIC CARBAMATES AND ISOXAZOLIDINES AS IIB/IIIA ANTAGONISTS DU PONT PHARMACEUTICALS COMPANY (US) 2000-01-06 WO disclosed